Genital Herpes / Genitalni herpes

1. Hook E W III. An evolving understanding of genital herpes pathogenesis: is it time for our approach to therapy to change as well? Editorial. J Infect Dis 2010;201:486-7.10.1086/650303Search in Google Scholar

2. Le Cleach L, Trinquart L, Lebrun-Vignes B, Giraudeau B, Chosidow O. Oral antiviral therapy for prevention of genital herpes outbreaks in immunocompetent and nonpregnant patients (Protocol). The Cochrane Library 2011;3 [serial on the Internet]. 2011[cited 2011 Apr 15];3. Available from: http://onlinelibrary. wiley.com/o/cochrane/clsysrev/articles/CD009036/pdf_fs.html10.1002/14651858.CD009036Search in Google Scholar

3. Gupta R, Warren T, Wald A. Genital herpes. Lancet 2007;370(9605):2127-37.10.1016/S0140-6736(07)61908-4Search in Google Scholar

4. Scoular A, Norrie J, Gillespie G, et al. Longitudinal study of genital infection by herpes simplex virus type 1 in Western Scotland over 15 years. BMJ 2002;324:1366-7.10.1136/bmj.324.7350.136611521212052804Search in Google Scholar

5. Pen KC, Adelson ME, Mordechai E,2 and ohn. Blaho JA. Genital Herpes Simplex Virus Type 1 in Women: Detection in Cervicovaginal Specimens from Gynecological Practices in the United States. J Clin Microbiol 2010;48(1):150-3.10.1128/JCM.01336-09281229119923487Search in Google Scholar

6. Looker KJ, Garnett PG, Schmid GP. An estimate of the globalprevalence and incidence of herpes simplex virus type 2 infection. Bull World Health Organ 2008;86(10):805-12.10.2471/BLT.07.046128264951118949218Search in Google Scholar

7. Leone P, Fleming DT, Gilsenan AW, Li L, Justus S. Seroprevalence of herpes simplex virus-2 in suburban primary care offices in the United States. Sex Transm Dis 2004; 31(5):311-6.10.1097/01.OLQ.0000123651.84697.D6Search in Google Scholar

8. Wald A, Zeh J, Selke S, et al. Reactivation of genital herpes simplex virus type 2 infection in asymptomatic seropositive persons. N Engl J Med 2000;342(12):844-50.10.1056/NEJM20000323342120310727588Search in Google Scholar

9. Tata S, Johnston C, Huang ML, Selke S, Magaret A,Corey L, et al. Overlapping reactivations of herpes simplex virus type 2 in the genital and perianal mucosa. J Infect Dis 2010;201:499-504.10.1086/650302281153320088691Search in Google Scholar

10. Zhu J, Koelle DM, Cao J, Vazquez J, Huang ML, Hladik F, et al. Virus specific CD8+ T cells acumulate near sensory nerve endings in genital skin during subclinical HSV-2 reactivation. J Exp Med 2007;204(3):595-603.10.1084/jem.20061792213791017325200Search in Google Scholar

11. Patel R, Alderson S, Geretti A, Nilsen A, Foley E, Lautenschlager S, et al. 2010 European guideline for the management of genital herpes. [cited 2011 Apr 15]. Available from: http://www.iusti.org/ regions/europe/Euro_guideline_HSV_2010.pdf10.1258/ijsa.2010.01027821364059Search in Google Scholar

12. Sen P, Barton SE. Genital herpes and its management. BMJ 2007;334(7602):1048-52.10.1136/bmj.39189.504306.55187180717510153Search in Google Scholar

13. Domeika M, Bashmakova M, Savicheva A, Kolomiec N, Sokolovskiy E, Hallen A, et al. Eastern European Network for Sexual and Reproductive Health (EE SRH Network). Guidelines for the laboratory diagnosis of genital herpes in eastern European countries. Eurosurveillance [serial on the Internet] 2010 [cited 2011 Apr 15];44:1-7. Available from: http://www.eurosurveillance.org/images/dynamic/EE/V15N44/art19703.pdf10.2807/ese.15.44.19703-en21087585Search in Google Scholar

14. Corey L, Wald A. Genital herpes. In: KK Holmes, PF Sparling, WE Stamm, P Piot, J W Wasserheit, L Corey, et al, editors. Sexually transmitted diseasesć 4th ed. New York: McGraw Hill; 2008. p. 399-437.Search in Google Scholar

15. Engelberg R, Carell D, Krantz E,Corey I, Wald A. Natural history of genital herpes simplex virus type 1 infection. Sex Transm Dis 2003;30(2):174-7.10.1097/00007435-200302000-0001512567178Search in Google Scholar

16. Saeed K, Pelosi E. Comparison between turnaround time and cost of herpes simplex virus testing by cell culture and polymerase chain reaction from genital swabs. Int J STD AIDS 2010;21:298-9.10.1258/ijsa.2009.00900620378906Search in Google Scholar

17. Gerreti AM, Brown DW. National survey of diagnostic services for genital herpes. Sex Transm Infect 2005;81:316-7.10.1136/sti.2004.013110174501316061538Search in Google Scholar

18. Goldman B D. Herpes Serology for Dermatologists Arch Dermatol 2000;136:1158-61Search in Google Scholar

19. Morrow R, Friedrich D. Performance of a novel test for IgM and IgG antibodies in subjects with culture-documented genital herpes simplex virus-1 or -2 infection. Clin Microbiol Infect 2006;12:463-9.10.1111/j.1469-0691.2006.01370.x16643524Search in Google Scholar

20. Cowan FM, Johnson AM, Ashley R, Corey L, Midel A. Relationship between antibodies to herpes simplex virus (HSV) and symptoms of HSV infection. J Infect Dis 1996;174:470-5.10.1093/infdis/174.3.4708769602Search in Google Scholar

21. Munday PE, Vuddamalay J, Slomka MJ, Brown DW. Role of type specific herpes simplex virus serology in the diagnosis and management of genital herpes. Sex Transm Infect 1998;74:175-8.10.1136/sti.74.3.17517581099849551Search in Google Scholar

22. Ashley RL, Eagleton M, Pfeiffer N. Ability of a rapid serology test to detect seroconversion to herpes simplex virus type 2 glycoprotein G soon after infection. J Clin Microbiol 1999;37:1632-3.10.1128/JCM.37.5.1632-1633.19998486010203544Search in Google Scholar

23. Laderman EI, Whitworth E, Dumaual E, Jones M, Hudak A, Hogrefe W, et al. Rapid, sensitive, and specific lateral-flow immunochromatographicnpoint-of-care device for detection of herpes simplex virus type 2-specific immunoglobulin G antibodies in serum and whole blood. Clin Vaccine Immunol 2008;15(1):159-63.10.1128/CVI.00218-07Search in Google Scholar

24. Corey L, Wald A, Patel R, et al. Once-daily valaciclovir to reduce the risk of transmission of genital herpes. N Engl J Med 2004;350:11-20.10.1056/NEJMoa035144Search in Google Scholar

25. Conant MA, Schacker TW, Murphy RL, Gold J, Crutchfield LT, Crooks RJ; International Valaciclovir HSV Study Group.Int J STD AIDS 2002 Jan;13(1):12-21.10.1258/0956462021924550Search in Google Scholar

26. Lingappa, JR; Baeten, JM; Wald, A; Daily aciclovir for HIV-1 disease progression in people dually infected with HIV-1 and herpes simplex virus type 2: a randomized placebo-controlled trial. Lancet 2010; 375:9717:824-33.10.1016/S0140-6736(09)62038-9Search in Google Scholar

27. Sheffield JS, Hill JB, Hollier LM, Laibl VR, Roberts SW, Sanchez PJ, Wendel GD Jr Valacylovir prophylaxis to prevent recurrent herpes at delivery: a randomised clinical trial. Obstet Gynecol 2006;108:141-7.10.1097/01.AOG.0000219749.96274.1516816068Search in Google Scholar

28. Drake AL, John-Stewart GC, Wald A et al. Herpes simplex virus type 2 and the risk of intrapartum human immunodeficiency virus transmission. Obstet Gynecol 2007; 10;403-9.10.1097/01.AOG.0000251511.27725.5c17267842Search in Google Scholar

29. Jovanović M, Karadaglić Đ, Golušin Z, Brkić S, Poljački M. Experimental vaccines for prevention sexually transmitted infections. [Eksperimentalne vakcine za prevenciju polno prenosivih infekcija]. Med Pregl 2009;62:42-8..10.2298/MPNS0902042JSearch in Google Scholar

30. Garnett GM. Role of herd immunity in determing the effect of vaccines against transmitted disease.J Infect Dis 2005;191(Suppl 1):S97-106.10.1086/42527115627236Search in Google Scholar

31. Rupp R, Stanberry LR, Rosenthal SL. New biomedicalapproaches for sexually transmitted infection prevention: vaccines and microbicides. Adolesc Med Clin 2004;15:393-407.10.1016/j.admecli.2004.02.01015449851Search in Google Scholar

32. Stanberry LR, Spruance SL, Cunningham AL, Bernstein DI, Mindel A, Sacks S, et al. Glycoprotein-D-sdjuvant vaccine to prevent genital herpes. N Eng J Med 2002;347:1652-61.10.1056/NEJMoa01191512444179Search in Google Scholar

33. Rupp R, Stanberry LR, Rosenthal SL. Vaccines for sexually transmitted infections. Pediatr Ann 2005;34(10):818-24.10.3928/0090-4481-20051001-14Search in Google Scholar

34. Garnett GP, Dubin G, Slaoui M, Darcis T. The potential epidemiological impact of a genital herpes vaccine for women. Sex Transm Infect 2004;80:24-9.10.1136/sti.2002.003848Search in Google Scholar

35. Straus SE, Corey L, Burke RL, et al. Placebo-controlled trial of vaccination with recombinant glycoprotein D of herpes simplex virus type 2 for immunotherapy of genital herpes. Lancet 1994; 343: 1460-1463.10.1016/S0140-6736(94)92581-XSearch in Google Scholar

36. Casanova G, Cancela R, Alonzo L, et al. A double-blind studyof the efficacy and safety of the ICP10deltaPK vaccine against recurrent genital HSV-2 infections. Cutis 2002; 70: 235-239.Search in Google Scholar

37. Gallichan WS, Rosenthal KL. Specific secretory immune response in the female genital tract following intranasal immunization with a recombinant adenovirus expressing glycoprotein B of herpes simplex virus. vaaccine 1995;13:1589-95.10.1016/0264-410X(95)00100-FSearch in Google Scholar

38. Hoshino Y, Pesnicak L, Dowdell KC, Lacayo J, Dudek T, Knipe DM, et al.Comparison of immunogenicity and protective efficacy of genital herpes vaccine candidates herpes simplex virus 2 dl5-29 and dl5-29-41L in mice and guinea pigs. Vaccine 2008;26:4034-40.10.1016/j.vaccine.2008.05.022256496418565628Search in Google Scholar

39. Campo JD, Lindqvist M, Cuello M, Backstrom M, Cabrerra O, Persson J, et al. Intranasal immunization with a proteoliposomederived cochleate containing recombinant gD protein confers protective immunity against genital herpes in mice. Vaccine 2010; 28:1193-200.10.1016/j.vaccine.2009.11.03519945418Search in Google Scholar